BioCentury | Nov 25, 2020
Product Development

Nov. 25 Quick Takes: FDA approves Y-mAbs’ Danyelza; plus NIH’s ACTT-4; COVAXX, Urovant, SomaLogic, Eluminex and Liquidia

...Asset Management, the Fiscus Ventures and Reimagined Ventures affiliates of Magnetar Capital, Monashee Investment Management, Mossrock Capital...
BioCentury | Sep 14, 2015
Financial News

Aclaris completes venture financing

...$40 million Investors: RA Capital Management; Cormorant Asset Management; Rock Springs Capital; Aperture Venture Partners; Mossrock Capital...
BioCentury | Sep 10, 2015
Financial News

Aclaris raises $40M, licenses Rigel's JAK inhibitors

...funding led by RA Capital; Cormorant Asset Management; Rock Springs Capital; Aperture Venture Partners; and Mossrock Capital...
Items per page:
1 - 3 of 3
BioCentury | Nov 25, 2020
Product Development

Nov. 25 Quick Takes: FDA approves Y-mAbs’ Danyelza; plus NIH’s ACTT-4; COVAXX, Urovant, SomaLogic, Eluminex and Liquidia

...Asset Management, the Fiscus Ventures and Reimagined Ventures affiliates of Magnetar Capital, Monashee Investment Management, Mossrock Capital...
BioCentury | Sep 14, 2015
Financial News

Aclaris completes venture financing

...$40 million Investors: RA Capital Management; Cormorant Asset Management; Rock Springs Capital; Aperture Venture Partners; Mossrock Capital...
BioCentury | Sep 10, 2015
Financial News

Aclaris raises $40M, licenses Rigel's JAK inhibitors

...funding led by RA Capital; Cormorant Asset Management; Rock Springs Capital; Aperture Venture Partners; and Mossrock Capital...
Items per page:
1 - 3 of 3